Calidi Biotherapeutics (CLDI) Other Non-Current Assets (2021 - 2025)
Calidi Biotherapeutics' quarterly Other Non-Current Assets came in at $138000.0 in Q4 2025, down 9.21% year-on-year from $152000.0 in Q4 2024, and down 1.43% quarter-over-quarter from $140000.0 in Q3 2025.
Calidi Biotherapeutics has reported Other Non-Current Assets for 5 years, with the latest figure at $138000.0 in Q4 2025.
- For the quarter ending Q4 2025, Other Non-Current Assets fell 9.21% year-over-year to $138000.0; the trailing twelve-month figure through Dec 2025 stood at $138000.0 (down 9.21% YoY), and the FY2025 full-year result was $138000.0, down 9.21% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $138000.0, down from $140000.0 in the prior quarter.
- The five-year high for Other Non-Current Assets was $725000.0 in Q4 2022, with the low at $40000.0 in Q2 2025.
- Average Other Non-Current Assets over 5 years is $246783.2, with a median of $200000.0 recorded in 2023.
- Year-over-year, Other Non-Current Assets soared 158.06% in 2022 and tumbled 82.38% in 2025.
- Tracing CLDI's Other Non-Current Assets over 5 years: stood at $280944.0 in 2021, then soared by 158.06% to $725000.0 in 2022, then plunged by 48.55% to $373000.0 in 2023, then plunged by 59.25% to $152000.0 in 2024, then fell by 9.21% to $138000.0 in 2025.
- The last three Other Non-Current Assets figures came in at $138000.0 (Q4 2025), $140000.0 (Q3 2025), and $40000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 2.13 Bn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | 138,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 138,000.00 |
| Sep 30, 2025 | 140,000.00 |
| Jun 30, 2025 | 40,000.00 |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 152,000.00 |
| Sep 30, 2024 | 217,000.00 |
| Jun 30, 2024 | 227,000.00 |
| Mar 31, 2024 | 506,000.00 |
| Dec 31, 2023 | 373,000.00 |
| Sep 30, 2023 | 200,000.00 |
| Dec 31, 2022 | 725,000.00 |
| Jun 30, 2022 | 77,033.00 |
| Mar 31, 2022 | 178,988.00 |
| Dec 31, 2021 | 280,944.00 |